Published On: Mon, May 10th, 2021

Lupin strikes deal with Lilly for Covid-19 drug Baricitinib in India

Tagged with: | | | | | |

Lupin Limited said that it has signed a royalty-free, limited, non-exclusive voluntary licensing agreement with Eli Lilly and Company (Lilly) for manufacturing and selling the latter’s in India.

Baricitinib is an oral JAK1/JAK2 inhibitor for which India’s Central Drugs Standard Control Organization (CDSCO) had been given restricted emergency use in combination with Remdesivir for the treatment of Covid-19 in hospitalized adults needing supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Lupin strikes deal with Lilly for Covid-19 drug Baricitinib in India

Lupin strikes deal with Lilly for drug Baricitinib in India. Image courtesy of Pete Linforth from Pixabay.

Baricitinib was earlier registered in India for the of adults having moderate to severe active rheumatoid .

Lupin stated: “With a rapid increase in active COVID-19 cases in India, the timely restricted emergency use of Baricitinib will be an important life-saving treatment for with moderate to severe symptoms of COVID-19.”

Related posts

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>